Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

Inclusion Criteria: * Patients with NSTE-ACS (UA or NSTEMI) undergoing PCI. NSTE-ACS will be defined as the presence of cardiac ischemic symptoms with ischemic changes (but not ST-segment elevation) on electrocardiogram with or without a positive troponin. However, normal electrocardiograms will be acceptable if the investigator will consider an ACS presentation likely. * Age between 18 and 75 years old Exclusion Criteria: * Inability to provide written informed consent * Age \>75 years * Weight \<60 Kg * ST-segment elevation myocardial infarction * On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 7 days * Known allergies to prasugrel or cangrelor * Considered at high risk for bleeding * History of ischemic or hemorrhagic stroke or transient ischemic attack * On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxoban) * Planned treatment with glycoprotein IIb/IIIa inhibitors (only bailout use allowed) * Fibrinolytics within 24 hours * Known platelet count \<80x106/mL * Known hemoglobin \<10 g/dL * Active bleeding * Known end stage renal disease on hemodialysis * Known severe hepatic dysfunction * Intubated patients (prior to randomization) * Pregnant females \[women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study\]